Neoadjuvant chemotherapy for locally advanced cancer

doi:10.3760/cma.j.issn.1673-422X.2015.12.009

Abstract

Liu Hui, Rui Jing. Neoadjuvant chemotherapy for locally advanced cancer[J]. Journal of International Oncology, 2015, 42(12): 916-919.

［1］ Zardavas D, Piccart M. Neoadjuvant therapy for breast cancer［J］. Annu Rev Med, 2015, 66: 31-48. ［2］ Zaharia M, Gómez H. Neoadjuvant chemotherapy in the treatment of locally advanced breast cancer［J］. Rev Peru Med Exp Salud Publica, 2013, 30(1): 73-78. ［3］ Cardoso F, Costa A, Norton L, et al. ESOESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)［J］. Ann Oncol, 2014, 23(5): 489-502. ［4］ Guha M. PARP inhibitors stumble in breast cancer［J］. Nat Biotechnol, 2011, 29(5): 373-374. ［5］ Silver D, Richardson A, Eklund A, et al. Efficacy of neoadjuvant cisplatin in triplenegative breast cancer［J］. J Clin Oncol, 2010, 28(7): 1145-1153. ［6］ Sikov WM, Berry DA, Perou CM, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant onceperweek paclitaxel followed by dosedense doxorubicin and cyclophosphamide on pathologic complete response rates in stage Ⅱ to Ⅲ triplenegative breast cancer: CALGB 40603 (Alliance)［J］. J Clin Oncol, 2015, 33(1): 13-21. ［7］ Pierga JY, Delaloge S, Espié M, et al. A multicenter randomized phase Ⅱ study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients［J］. Breast Cancer Res Treat, 2010, 122(2): 429-473. ［8］ Earl HM, Vallier AL, Hiller L, et al. Effects of the addition of gemcitabine, and paclitaxelfirst sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with highrisk early breast cancer (NeotAnGo): an openlabel, 2×2 factorial randomised phase 3 trial［J］. Lancet Oncol, 2014, 15(2): 201-212. ［9］ Vriens BE, Aarts MJ, de Vries B, et al. Doxorubicin/cyclophosphamide with concurrent versus sequential docetaxel as neoadjuvant treatment in patients with breast cancer［J］. Eur J Cancer, 2013, 49 (15): 3102-3110. ［10］ Eiermann W, Pienkowski T, Crown J, et al. Phase Ⅲ study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2normal, nodepositive breast cancer: BCIRG005 trial［J］. J Clin Oncol, 2011, 29(29): 3877-3884. ［11］ Untch M, Fasching PA, Konecny GE, et al. PREPARE trial: a randomized phase Ⅲ trial comparing preoperative, dosedense, doseintensified chemotherapy with epirubicin, paclitaxel and CMF versus a standarddosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer—results at the time of surgery［J］. Ann Oncol, 2011, 22(9): 1988-1998. ［12］ von Minckwitz G, Blohmer JU, Costa SD, et al. Responseguided neoadjuvant chemotherapy for breast cancer［J］. J Clin Oncol, 2013, 31(29): 3623-3630. ［13］ Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2negative cohort［J］. Lancet, 2010, 375(9712): 377-384. ［14］ Untch M, Rezai M, Loibl S, et al. Neoadjuvant treatment with trastuzumab in HER2positive breast cancer: results from the GeparQuattro study［J］. J Clin Oncol, 2010, 28(12): 2024-2031. ［15］ Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with trastuzumab for HER2positive early breast cancer (NeoALTTO): a randomised, openlabel, multicentre, phase 3 trial［J］. Lancet, 2012, 379(9816): 633-640. ［16］ Robidoux A, Tang G, Rastogi P, et al. Lapatinib as a component of neoadjuvant therapy for HER2positive operable breast cancer (NSABP protocol B41): an openlabel, randomised phase 3 trial［J］. Lancet Oncol, 2013, 14(12): 1183-1192. ［17］ Rimawi MF, Mayer IA, Forero A, et al. Multicenter phase Ⅱ study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2overexpressing breast cancer: TBCRC 006［J］. J Clin Oncol, 2013, 31(14): 1726-1731. ［18］ Swain SM, Kim SB, Cortés J, et al. Pertuzumab, trastuzumab, and docetaxel for HER2positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, doubleblind, placebocontrolled, phase 3 study［J］. Lancet Oncol, 2013, 14(6): 461-471. ［19］ Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2positive breast cancer (NeoSphere): a randomised multicentre, openlabel, phase 2 trial［J］. Lancet Oncol, 2012, 13(1): 25-32. ［20］ Schneeweiss A, Chia S, Hickish T, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracyclinecontaining and anthracyclinefree chemotherapy regimens in patients with HER2positive early breast cancer: a randomized phase Ⅱ cardiac safety study (TRYPHAENA)［J］. Ann Oncol , 2013, 24(9): 2278-2284. ［21］ Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2positive advanced breast cancer［J］. N Engl J Med, 2012, 367(19): 1783-1791. ［22］ Pierga JY, Petit T, Delozier T, et al. Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2positive breast cancer (BEVERLY2): an openlabel, singlearm phase 2 study［J］. Lancet Oncol, 2012, 13(4): 375-384. ［23］ Coudert B, Pierga JY, MouretReynier MA, et al. Use of ［(18)F］FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in ［(18)F］FDG PETpredicted nonresponders (AVATAXHER): an openlabel, randomised phase 2 trial［J］. Lancet Oncol, 2014, 5(13): 1493-1502. ［24］ Iqbal J, Bano K, Saeed A, et al. Survival of women with locally advanced breast cancer at a teaching hospital in Lahore［J］. J Pak Med Assoc, 2010, 60(9): 721-725. ［25］ von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes［J］. J Clin Oncol, 2012, 30(15): 1796-1804. ［26］ de Azambuja E, Holmes A, PiccartGebhart M, et al. Lapatinib with trastuzumab for HER2positive early breast cancer (NeoALTTO): survival outcomes of a randomised, openlabel, multicentre, phase 3 trial and their association with pathological complete response［J］. Lancet Oncol, 2014, 15(10): 1137-1146.

[1]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[2]	Sa Qiang, Xu Hangcheng, Wang Jiayu. Advances in immunotherapy for breast cancer [J]. Journal of International Oncology, 2024, 51(4): 227-234.
[3]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong. Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer [J]. Journal of International Oncology, 2024, 51(4): 235-238.
[4]	Chen Boguang, Wang Sugui, Zhang Yongjie. Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer [J]. Journal of International Oncology, 2024, 51(2): 73-82.
[5]	Gu Huayan, Zhu Teng, Guo Guilong. Breast microbiota and breast cancer： present and future [J]. Journal of International Oncology, 2024, 51(1): 55-58.
[6]	Wang Jing, Xu Wenting. Value of NLR， CEA combined with coagulation indicators in the differential diagnosis of benign and malignant breast nodules with a diameter ≤ 1.0 cm [J]. Journal of International Oncology, 2023, 50(9): 520-526.
[7]	Feng Chengtian, Huang Furong, Cao Shiyu, Wang Jianyu, Nanding Abiyasi, Jiang Yongdong, Zhu Juanying. Relationships between HER2 protein expression and imaging features in HER2 positive breast cancer patients [J]. Journal of International Oncology, 2023, 50(9): 527-531.
[8]	Feng Dongxu, Wu Wei, Gao Pingfa, Wang Jun, Shi Lijuan, Chen Dawei, Li Wenbing, Zhang Meifeng. Effects of miR-451 on glycolysis and apoptosis of breast cancer cells by regulating Rho/ROCK1 pathway [J]. Journal of International Oncology, 2023, 50(8): 449-456.
[9]	Pan Shulan, Liu Chang, He Ping. Effect of fritinib on angiogenesis, tumor growth and IRE1-ASK1-JNK pathway in triple negative breast cancer [J]. Journal of International Oncology, 2023, 50(8): 457-462.
[10]	Wang Wende, Zeng De. Research progress on the mechanism of endocrine therapy resistance for breast cancer [J]. Journal of International Oncology, 2023, 50(6): 352-356.
[11]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai. Research progress on the application of combining radiotherapy and systemic therapy in breast cancer [J]. Journal of International Oncology, 2023, 50(6): 362-367.
[12]	Zhu Jun, Huang Meijin, Li Yuan, Liu Zegang, Xun Xin, Chen Hong. Research progress on targeted therapy of breast cancer with low expression of HER2 [J]. Journal of International Oncology, 2023, 50(4): 236-240.
[13]	Zhou Ting, Xu Shaohua, Mei Lin. Efficacy and safety of bevacizumab combined with capecitabine in the treatment of advanced breast cancer [J]. Journal of International Oncology, 2023, 50(3): 144-149.
[14]	Fan Shanlin, Wang Pinxiu, Kong Fei, Zhou Yujie, Yuan Wenzhen. Progress in the study of predictors of tumor regression grade after neoadjuvant chemotherapy for gastric cancer [J]. Journal of International Oncology, 2023, 50(2): 112-116.
[15]	Li Lixi, Zhang Di, Luo Yang, Ma Fei. Clinical application of PARP inhibitors in breast cancer [J]. Journal of International Oncology, 2023, 50(2): 91-96.

Neoadjuvant chemotherapy for locally advanced cancer

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments